Free Shipping in the U.S. for orders over $1000.  Shop Now>>

Recombinant Transforming Growth Factor Beta Receptor 1 (TGFBR1) Antibody [rG3E6]

In Stock
Catalog Number Formulation Size Price
7046-MSM3-P0
Purified Ab with BSA and Azide at 200ug/ml
20ug
$249.00
7046-MSM3-P1
Purified Ab with BSA and Azide at 200ug/ml
100ug
$539.00
7046-MSM3-P1ABX
Purified Ab WITHOUT BSA and Azide at 1.0mg/ml
100ug
$539.00
Flat Rate Domestic: $75 | Orders outside the US - Contact Us for Order Information | Ships next business day

Applications & Dilutions

Applications Tested Dillution Protocol Note
Immunohistochemistry (IHC)
1-2ug/ml
30 min at RT. Staining of formalin-fixed tissues requires heating tissue sections in 10mM Tris with 1mM EDTA, pH 9.0, for 45 min at 95°C followed by cooling at RT for 20 minutes

Summary

Transforming growth factor beta (TGFB) inhibits cell proliferation and stimulates cell differentiation. This is achieved through a receptor complex of types I and II TGFB receptors. The type II receptor is a transmembrane serine/threonine kinase which is able to bind TGFB and transactivate the type I receptor. TGFB receptors are found in all myometrial tissues and, in the kidney, they are found exclusively in renal tubular cells. In normal gastric mucosa, type I and II receptors are demonstrated in fundic glands, but not on surface mucous cells and in normal small bowel and colon, TGFB receptors are expressed in the epithelial cells of the upper crypts.

Product Properties & Targets

Host
Mouse
Applications
Species Reactivity
Isotype / Light Chain
IgM / Kappa
Cellular Localization
Cell membrane, Cell surface, Cytoplasm
Gene Name
Positive Control
Human placenta, spleen or liver. HEK293T cells.
Immunogen
Prokaryotic recombinant protein corresponding to the external domain of the human transforming growth factor beta receptor type 1 molecule
Alternate Names
TGF-beta receptor type-1, Activin A receptor type II-like protein kinase of 53kD, Activin receptor-like kinase 5 (ALK-5; ALK5), Serine/threonine-protein kinase receptor R4 (SKR4), TGF-beta type I receptor, Transforming growth factor-beta receptor type I (TGF-beta receptor type I; TbetaR-I), ALK5 | SKR4

Database Links

Entrez Gene ID
SwissProt

Additional Information

Clone
rG3E6
Chromosome Location
9q22.33
Mol. Weight of Antigen
53kDa

Functions

  • Transmembrane serine/threonine kinase forming with the TGF-beta type II serine/threonine kinase receptor, TGFBR2, the non-promiscuous receptor for the TGF-beta cytokines TGFB1, TGFB2 and TGFB3. Transduces the TGFB1, TGFB2 and TGFB3 signal from the cell surface to the cytoplasm and is thus regulating a plethora of physiological and pathological processes including cell cycle arrest in epithelial and hematopoietic cells, control of mesenchymal cell proliferation and differentiation, wound healing, extracellular matrix production, immunosuppression and carcinogenesis (PubMed:33914044). The formation of the receptor complex composed of 2 TGFBR1 and 2 TGFBR2 molecules symmetrically bound to the cytokine dimer results in the phosphorylation and the activation of TGFBR1 by the constitutively active TGFBR2. Activated TGFBR1 phosphorylates SMAD2 which dissociates from the receptor and interacts with SMAD4. The SMAD2-SMAD4 complex is subsequently translocated to the nucleus where it modulates the transcription of the TGF-beta-regulated genes. This constitutes the canonical SMAD-dependent TGF-beta signaling cascade. Also involved in non-canonical, SMAD-independent TGF-beta signaling pathways. For instance, TGFBR1 induces TRAF6 autoubiquitination which in turn results in MAP3K7 ubiquitination and activation to trigger apoptosis. Also regulates epithelial to mesenchymal transition through a SMAD-independent signaling pathway through PARD6A phosphorylation and activation.

Key References

  • Chegini N, Ma C, Davis J, et al. Journal of the Society of Gynecological Investigation. 6 (5):258–263 (1999).
  • di Mola F F, Friess H, Scheuren A, et al. Annals of Surgery. 229 (1): 67–75 (1999).
  • Matsushita M, Matsuzaki K, Date M, et al. British Journal of Cancer. 80 (1–2): 194–205 (1999).
  • Tokunaga H, Lee D H, Kim I Y, et al. Clinical Cancer Research. 5 (9): 2520–2525 (1999).
  • Lippa C F, Flanders K C, Kim E S, et al. Neurobiological Aging. 19 (6): 527–533 (1998).
  • Sutaria P M, Ohebshalom M, McCaffrey T A, et al. Life Science. 62 (21): 1965–1972 (1998).
  • Kai T, Taketazu F, Kawakami M, et al. Japanese Journal of Cancer Research. 87 (3): 296–304 (1996).
  • Ohtani H, Kagaya H and Nagura H. Journal of Gastroenterology. 8: 76–77 (1995).
  • Yamada N, Kato M, Yamashita H, et al. International Journal of Cancer. 62 (4): 386–392 (1995).

Storage & Stability

Antibody with azide - store at 2 to 8°C. Antibody without azide - store at -20 to -80°C. Antibody is stable for 24 months. Non-hazardous. No MSDS required.

Limitations

This antibody is available for research use only and is not approved for use in diagnosis.

Supplied as

200ug/ml of Ab produced in CHO cell mammalian-based expression system. Prepared in 10mM PBS with 0.05% BSA & 0.05% azide. Also available WITHOUT BSA & azide at 1.0mg/ml.

Warranty

There are no warranties, expressed or implied, which extend beyond this description. Company is not liable for any personal injury or economic loss resulting from this product.

Reviews

There are no reviews yet.

Be the first to review “Recombinant Transforming Growth Factor Beta Receptor 1 (TGFBR1) Antibody”

Your email address will not be published. Required fields are marked *

PARTNERSHIP OPPORTUNITIES

NeoBiotechnologies holds Exclusive rights to 10,000 recombinant and hybridoma antibody products, available for Licensing or Collaboration.

LETS TALK